Recent Comments

Comment RSS

Scleroderma News and Research RSS Feed - Scleroderma News and Research

Scleroderma is a chronic, often progressive, autoimmune disease in which the body's immune system attacks its own body. The disease, which literally means "hard skin," can cause a thickening and tightening of the skin. In some cases it causes serious damage to internal organs including the lungs, heart, kidneys, esophagus and gastrointestinal tract. Some medicines and treatments can help with certain symptoms, but there is still no cure for scleroderma, which affects about 300,000 nationwide. (By way of comparison, about 50,000 people have muscular dystrophy, 250,000 are estimated to have lupus and 350,000 have multiple sclerosis.)

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

20. November 2009 05:41
The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , ,

Cold weather can trigger Raynaud's disease

17. November 2009 01:53
Cold weather triggers a painful and sometimes debilitating disorder for millions of Americans who suffer from Raynaud's disease (also known as Raynaud's syndrome or phenomenon). Raynaud's is an autoimmune disorder in which spasms in the blood vessels can interrupt blood flow to the fingers, toes, nose and ears. Exposure to cold triggers the spasms, typically causing the affected area to turn white, then blue, then bright red. Emotional stress can also cause an attack. [More]

Posted in: Medical Condition News

Tags: , , , , , , ,

Research and Markets' Competitive Intelligence Report on TGF-R agonists and antagonists

11. November 2009 07:53
Research and Markets has announced the addition of the "Competitor Analysis: TGF-R Agonists and Antagonists" report to their offering. [More]

Daval International receives award for its anti-inflammatory agent AIMSPRO

9. November 2009 02:35
Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (http://www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS). [More]

Genetists identify gene signature expressed in skin associated with the occurrence of lung disease

30. October 2009 07:00
At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them. [More]

Recently approved Gleevec drug for cancer treatment

19. October 2009 02:00
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia. [More]

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

7. October 2009 01:15
Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority. [More]

Posted in: Device / Technology News

Tags: , , , ,

Reportlinker's medical review criteria guidelines for managing care

30. September 2009 08:03
Reportlinker Adds Medical Review Criteria Guidelines for Managing Care (8th ed. - 2009) [More]

Posted in: Healthcare News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Innovative treatments for bowel dysfunction

15. September 2009 01:01
Twenty percent of all Albertans are plagued by symptoms of diarrhea, constipation, abdominal pain, bloating, and gas. More than an inconvenience for many, these problems are rarely discussed in public, leaving sufferers feeling isolated. Yet bowel symptoms can be disabling, greatly impairing quality of life. [More]

Endothelin research update to be presented at APS' 11th International Conference

10. September 2009 23:12
Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. [More]

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

9. September 2009 04:25
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1. [More]

Report on autoimmune disease therapeutics in worldwide markets

9. September 2009 04:08
Reportlinker.com announces that a new market research report is available in its catalogue. Autoimmune Disease Therapeutics [More]

Victim’s longevity with the deadly disease inspires thousands of dying patients

5. September 2009 02:27
When Jerry Lewis takes the stage again on Labor Day 2009 for the Muscular Dystrophy Association Telethon, thousands of people who suffer from the same lung disease as he will be watching - and not just to hear the funny things he'll say. They'll be looking for inspiration from the funny man who suffers from a not-so-funny and little known fatal lung disease. [More]

Actelion launches new 20 mcg/mL Ventavis formulation

2. September 2009 04:12
Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. [More]

FDA approves Adcirca (tadalafil) tablets for pulmonary arterial hypertension

26. May 2009 05:40
United Therapeutics Corporation announced today that the United States Food and Drug Administration (FDA) has approved Adcirca (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.